NCT07075731 Cervical and Endometrial Cancer Screening in Patients Seeking Gender-Affirming Hysterectomy
| NCT ID | NCT07075731 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Minnesota |
| Condition | Cancer Screening |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-06-30 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2025-06-30 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to quantify the rates of cervical cancer screening and endometrial sampling prior to gender-affirming hysterectomy, assess the need for these tests in TGD individuals, and explore patient-centered options for these tests. By assessing the status of testing and correlation with hysterectomy pathology, this study will provide preliminary data on the current state of guideline-concordant care and provide initial evidence for the development of evidence-based guidelines in the future
Eligibility Criteria
Inclusion Criteria: * 18 years and older * Able to provide voluntary written consent prior to the performance of any research related activity. Patients who can provide informed consent * Able to understand, speak, read, and write in English * Patients who have undergone hysterectomy, or plan to have a hysterectomy * Patients who are transgender and gender diverse" Exclusion Criteria: * Opted out of research * \<18 years old * Lacks capacity to consent/has diminished capacity to consent * Cannot provide informed consent * Those on the study's community advisory board
Contact & Investigator
Samantha Hoffman, MD
PRINCIPAL INVESTIGATOR
University of Minnesota
Frequently Asked Questions
Who can join the NCT07075731 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer Screening. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07075731 currently recruiting?
Yes, NCT07075731 is actively recruiting participants. Contact the research team at kehoe018@umn.edu for enrollment information.
Where is the NCT07075731 trial being conducted?
This trial is being conducted at Minneota, United States.
Who is sponsoring the NCT07075731 clinical trial?
NCT07075731 is sponsored by University of Minnesota. The principal investigator is Samantha Hoffman, MD at University of Minnesota. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.